SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 77.06 |
| Enterprise Value ($M) | 2.35 |
| Book Value ($M) | 81.12 |
| Book Value / Share | 2.81 |
| Price / Book | 0.95 |
| NCAV ($M) | 78.76 |
| NCAV / Share | 2.73 |
| Price / NCAV | 0.98 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -0.36 |
| Return on Equity (ROE) | -0.38 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 9.35 |
| Current Ratio | 9.35 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 89.94 |
| Assets | 92.31 |
| Liabilities | 11.19 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | StemPoint Capital LP | 8.20 | ||
| 13G/A | Great Point Partners Llc | 6.88 | -24.69 | |
| 13G/A | Biotechnology Value Fund L P | 9.97 | 11.06 | |
| 13G/A | Nantahala Capital Management, LLC | 9.99 | 1.31 | |
| 13G/A | Citadel Advisors Llc | 4.20 | ||
| 13G/A | Point72 Asset Management, L.P. | 3.00 | -47.48 | |
| 13G | Vanguard Group Inc | 6.79 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 Form 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 40,164 | 169,640 | 23.68 | |
| 29,492 | 133,824 | 22.04 | |
| 25,218 | 99,853 | 25.26 | |
| 151,713 | 259,721 | 58.41 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| VKTX – Viking Therapeutics, Inc. | VRPX – Virpax Pharmaceuticals, Inc. |
| VSTM – Verastem, Inc. | VTVT – vTv Therapeutics Inc. |
| VXRT – Vaxart, Inc. |
Financial data and stock pages provided by
Fintel.io